摘要
目的观察艾普拉唑联合康复新液治疗门脉高压性胃病的临床效果。方法将49例门脉高压性胃病患者随机分为试验组25例和对照组24例。对照组予艾普拉唑治疗,试验组在对照组基础上予康复新液治疗。观察2组临床症状、胃黏膜改善情况及不良反应情况。结果试验组临床症状和胃黏膜改善总有效率均高于对照组,差异有统计学意义(P<0.05)。结论艾普拉唑联合康复新液治疗门脉高压性胃病疗效显著,可明显改善患者临床症状,且无不良反应,值得临床推广应用。
Objective To observe the clinical efficacy of ilaprazole combined with Kangfuxin solution in the treatment of portal hypertensive gastropathy. Methods 49 cases patients with portal hypertension gastropathy were randomly divided into experiment group （25 cases） and control group （24 cases）. Control group were treated with ilaprazole; experiment group, on basis of control group,were treated with Kangfuxin solution. Observed the clinical symptoms,gastric improvement and adverse reactions of two groups. Results Improved clinical symptoms and gastric total effective rate of experiment group were higher than those of control group,the difference was statistically significant （ P 〈 0.05 ）. Conclusion Ilaprazole combined with Kangfuxin solution in the treatment of portal hypertensive gastropathy has significant effect, can significantly improve clinical symptoms, and has no adverse reactions ,worthy of clinical application.
出处
《临床合理用药杂志》
2013年第31期34-35,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
胃病
门脉高压性
艾普拉唑
康复新液
Stomach,portal hypertension
Ilaprazole
Kangfuxin solution
